{"id":"homoharringtonine","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Febrile neutropenia","drugRate":"33.3%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":3,"totalAffected":1,"trialsReporting":1},{"effect":"General disorders and administration site conditions - Other, specify","drugRate":"33.3%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":3,"totalAffected":1,"trialsReporting":1},{"effect":"Abdominal Pain","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Aspartate aminotransferase increased","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Creatinine increased","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Ejection fraction decreased","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Hypokalemia","drugRate":"0.0%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Hypophosphatemia","drugRate":"0.0%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Hypoxia","drugRate":"0.0%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Infections and infestations - Other, specify","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Leukocytosis","drugRate":"0.0%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Mucositis oral","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Nausea","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Pleural effusion","drugRate":"0.0%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1},{"effect":"Sepsis","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":3,"totalAffected":0,"trialsReporting":1}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"event":"Febrile neutropenia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"33.3%"},{"event":"Non-neutropenic fever","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"33.3%"},{"event":"Hypoxia","detail":"Respiratory, thoracic and mediastinal disorders. 1 trial(s).","severity":"serious","incidence":"33.3%"},{"event":"Pneumonia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"33.3%"},{"event":"Nausea","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"33.3%"},{"event":"Right middle cerebellar peduncle and medullary lesion - (Brain Lesions)","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"33.3%"},{"event":"Slurred speech","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"33.3%"},{"event":"Acute hypoxic respiratory insufficiency","detail":"Respiratory, thoracic and mediastinal disorders. 1 trial(s).","severity":"serious","incidence":"33.3%"},{"event":"Sepsis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"33.3%"},{"event":"Soft tissue infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"33.3%"},{"event":"Vomiting","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"33.3%"},{"event":"Atrial fibrillation","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Confusion","detail":"Psychiatric disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Fall","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Fatigue","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Diverticulitis","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Failure to thrive","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Weakness","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypokalemia","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Lung infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Altered mental status","detail":"Psychiatric disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Renal Failure","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cellulitis of the right toe","detail":"Skin and subcutaneous tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Syncope","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL3774735","moleculeType":"Small molecule","molecularWeight":"545.63"},"aliases":["Omacetaxine mepesuccinate","CGX-635","HHT, Omacetaxine mepesuccinate","HHT","Dexamethasone"],"patents":[],"pricing":[],"_sources":{"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:43:18.906601+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T00:45:03.617Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:43:27.064435+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Chronic myeloid leukemia","diseaseId":"chronic-myeloid-leukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT04926285","phase":"PHASE1","title":"Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2022-06-21","conditions":"Relapsed or Refractory Hematologic Malignancies","enrollment":6},{"nctId":"NCT07469046","phase":"PHASE3","title":"VAH vs VA in Newly Diagnosed Elderly AML","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-01","conditions":"Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)","enrollment":308},{"nctId":"NCT06483906","phase":"PHASE2","title":"Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-07-02","conditions":"Acute Myeloid Leukemia","enrollment":56},{"nctId":"NCT07437170","phase":"PHASE2","title":"Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2024-01-01","conditions":"Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, NUP98 Fusion-positive Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT03165851","phase":"","title":"Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2005-04-10","conditions":"Acute Myeloid Leukemia, Pediatric","enrollment":320},{"nctId":"NCT07172204","phase":"PHASE2","title":"Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-16","conditions":"Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60","enrollment":25},{"nctId":"NCT05906914","phase":"PHASE2","title":"Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-10-26","conditions":"Acute Myeloid Leukemia, Adult","enrollment":65},{"nctId":"NCT07319793","phase":"NA","title":"Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS)","enrollment":200},{"nctId":"NCT03564873","phase":"PHASE1, PHASE2","title":"Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2018-09-17","conditions":"High Grade Myelodysplastic Syndromes","enrollment":28},{"nctId":"NCT07163910","phase":"PHASE2","title":"Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study","status":"RECRUITING","sponsor":"baotai Liang","startDate":"2025-04-20","conditions":"Prostate Cancer","enrollment":93},{"nctId":"NCT04874194","phase":"PHASE1, PHASE2","title":"Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-12-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT04501120","phase":"PHASE1, PHASE2","title":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-09-28","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":458},{"nctId":"NCT07159906","phase":"PHASE1, PHASE2","title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-08","conditions":"Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":62},{"nctId":"NCT06834321","phase":"PHASE2","title":"Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer","status":"RECRUITING","sponsor":"baotai Liang","startDate":"2025-03-19","conditions":"Prostate CA","enrollment":96},{"nctId":"NCT06855810","phase":"PHASE2, PHASE3","title":"Newly-diagnosed Pediatric T-cell ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-11","conditions":"Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma","enrollment":610},{"nctId":"NCT06265545","phase":"NA","title":"Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-02-22","conditions":"AML, Refractory, Relapsed","enrollment":120},{"nctId":"NCT07091006","phase":"PHASE2","title":"Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-01","conditions":"Relapse Leukemia","enrollment":44},{"nctId":"NCT04415008","phase":"PHASE2","title":"Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-06-01","conditions":"CEBPA Double Mutation, Acute Myeloid Leukemia","enrollment":61},{"nctId":"NCT05941585","phase":"NA","title":"Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-08-08","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT06744556","phase":"PHASE2","title":"HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-21","conditions":"AML","enrollment":60},{"nctId":"NCT04126681","phase":"PHASE2","title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-10-21","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":144},{"nctId":"NCT06361329","phase":"PHASE3","title":"Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-04-03","conditions":"ETP-ALL","enrollment":81},{"nctId":"NCT06810791","phase":"PHASE3","title":"HVA vs IA/DA or VA in the Treatment of ND HR-AML","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-01-01","conditions":"Newly Diagnosed Acute Myeloid Leukemia With High Risk","enrollment":876},{"nctId":"NCT06529250","phase":"NA","title":"Intermediate-dose HAD Regimen for CEBPA Double-mutated AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-13","conditions":"AML","enrollment":148},{"nctId":"NCT06742463","phase":"PHASE2","title":"VHAG in Treating R/R T-ALL/LBL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-12","conditions":"Acute T Lymphpblastic Leukemia/Lymphoma","enrollment":50},{"nctId":"NCT05726110","phase":"PHASE3","title":"Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2023-01-29","conditions":"Relapsed or Refractory Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT06635681","phase":"PHASE2","title":"Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-09-29","conditions":"AML (Acute Myelogenous Leukemia)","enrollment":1200},{"nctId":"NCT06221683","phase":"PHASE2","title":"Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-01-01","conditions":"AML, Childhood, Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT06470841","phase":"PHASE2","title":"CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2024-09-20","conditions":"Acute Myeloid Leukemia","enrollment":85},{"nctId":"NCT06394011","phase":"PHASE2","title":"Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-02-15","conditions":"Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT06328179","phase":"NA","title":"Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.","status":"RECRUITING","sponsor":"Huai'an First People's Hospital","startDate":"2022-05-24","conditions":"Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT05805072","phase":"NA","title":"Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-05-01","conditions":"Relapsed/Refractory AML","enrollment":20},{"nctId":"NCT05805098","phase":"PHASE2, PHASE3","title":"Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT05584761","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-03-01","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-2, Secondary Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT04248595","phase":"PHASE2","title":"Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML","status":"UNKNOWN","sponsor":"Ge Zheng","startDate":"2019-12-01","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT05513131","phase":"PHASE2","title":"Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-09-30","conditions":"Secondary Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT05457361","phase":"PHASE3","title":"VAH Versus VA for Salvage Therapy of R/R-AML","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-03-01","conditions":"Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine","enrollment":162},{"nctId":"NCT05456048","phase":"","title":"Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-12-03","conditions":"Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Gene Abnormality","enrollment":231},{"nctId":"NCT03873311","phase":"PHASE4","title":"Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy","status":"UNKNOWN","sponsor":"Shenzhen Second People's Hospital","startDate":"2019-09-01","conditions":"Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia","enrollment":114},{"nctId":"NCT00462943","phase":"PHASE2","title":"Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-03-07","conditions":"Chronic Myeloid Leukemia","enrollment":100},{"nctId":"NCT04722952","phase":"PHASE3","title":"PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-05-01","conditions":"Immunotherapy, Refractory Leukemia, Relapsed Adult AML","enrollment":30},{"nctId":"NCT00375219","phase":"PHASE2","title":"Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2006-09-20","conditions":"Chronic Myeloid Leukemia","enrollment":103},{"nctId":"NCT02078960","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-10-09","conditions":"Chronic Myeloid Leukemia","enrollment":10},{"nctId":"NCT04716114","phase":"PHASE3","title":"A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-03-24","conditions":"Acute Myeloid Leukemia (AML)","enrollment":315},{"nctId":"NCT02440568","phase":"PHASE1, PHASE2","title":"AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2015-06-05","conditions":"Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT02159872","phase":"PHASE2","title":"Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-05-18","conditions":"Leukemia","enrollment":48},{"nctId":"NCT03135054","phase":"PHASE2","title":"Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2017-10-01","conditions":"AML, FLT3-ITD Mutation","enrollment":40},{"nctId":"NCT04505995","phase":"NA","title":"Azacitidine and Homoharringtonine in JMML","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2020-01-01","conditions":"JMML","enrollment":30},{"nctId":"NCT04446130","phase":"PHASE3","title":"Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-01-01","conditions":"Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia","enrollment":100},{"nctId":"NCT03170895","phase":"PHASE2","title":"Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2017-07-01","conditions":"AML, FLT3-ITD Mutation","enrollment":5},{"nctId":"NCT01873495","phase":"PHASE2","title":"Omacetaxine for Consolidation and Maintenance","status":"TERMINATED","sponsor":"Emory University","startDate":"2013-05","conditions":"Acute Myelogenous Leukemia (AML)","enrollment":7},{"nctId":"NCT04087967","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":162},{"nctId":"NCT04083911","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":50},{"nctId":"NCT03978364","phase":"PHASE3","title":"A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2019-06-01","conditions":"Myelodysplastic Syndromes,Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT01272245","phase":"PHASE2","title":"Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-07","conditions":"Leukemia","enrollment":36},{"nctId":"NCT03453255","phase":"PHASE1, PHASE2","title":"DCHA as Postremission Therapy for AML With t(8;21)","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2018-01-01","conditions":"Chemotherapy","enrollment":120},{"nctId":"NCT02141477","phase":"PHASE1","title":"Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-05-06","conditions":"Leukemia","enrollment":2},{"nctId":"NCT02835794","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2016-08","conditions":"Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT01417767","phase":"PHASE2, PHASE3","title":"Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS","status":"UNKNOWN","sponsor":"Xiao Li","startDate":"2011-09","conditions":"Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT00004933","phase":"PHASE3","title":"Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2000-01","conditions":"Leukemia","enrollment":5},{"nctId":"NCT02029417","phase":"PHASE2","title":"Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2014-07","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","enrollment":2},{"nctId":"NCT01844869","phase":"PHASE1","title":"An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Hematologic Malignancies, Solid Tumors","enrollment":6},{"nctId":"NCT00114959","phase":"PHASE2","title":"Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)","status":"TERMINATED","sponsor":"ChemGenex Pharmaceuticals","startDate":"2005-10","conditions":"Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase","enrollment":15},{"nctId":"NCT00675350","phase":"PHASE1","title":"Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors","status":"COMPLETED","sponsor":"ChemGenex Pharmaceuticals","startDate":"2008-04","conditions":"Hematologic Tumors","enrollment":12},{"nctId":"NCT00003694","phase":"PHASE2","title":"Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-03","conditions":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia","enrollment":60},{"nctId":"NCT00030355","phase":"PHASE1, PHASE2","title":"Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00002574","phase":"PHASE2","title":"Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1994-09","conditions":"Leukemia","enrollment":87},{"nctId":"NCT00006364","phase":"PHASE2","title":"Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-11","conditions":"Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia","enrollment":50},{"nctId":"NCT00003239","phase":"PHASE2","title":"Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1998-03","conditions":"Leukemia","enrollment":90}],"_emaApprovals":[],"_faersSignals":[{"count":29,"reaction":"BONE MARROW FAILURE"},{"count":13,"reaction":"OFF LABEL USE"},{"count":13,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":12,"reaction":"MYELOSUPPRESSION"},{"count":11,"reaction":"NAUSEA"},{"count":10,"reaction":"LUNG INFECTION"},{"count":9,"reaction":"VOMITING"},{"count":7,"reaction":"DRUG INEFFECTIVE"},{"count":6,"reaction":"HEPATIC FUNCTION ABNORMAL"},{"count":6,"reaction":"INFECTION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":706,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"Homoharringtonine","genericName":"Homoharringtonine","companyName":"ChemGenex Pharmaceuticals","companyId":"chemgenex-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":4,"withResults":1},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:43:27.064435+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}